A 4-cuproptosis-related lncRNA theragnostic signature predicts survival and immunotherapy response in patients with lung adenocarcinoma.

ABSTRACT: Lung adenocarcinoma (LUAD), the most prevalent histological subtype of lung cancer worldwide, is associated with poor survival outcomes. Both cuproptosis and long non-coding RNAs (lncRNAs) demonstrate significant prognostic value and play emerging roles in LUAD immunotherapy. The aim of the present study was to identify a cuproptosis-related lncRNA signature for predicting survival and treatment response in patients with LUAD. Cuproptosis-related lncRNAs were screened from The Cancer Genome Atlas-LUAD cohort using Pearson correlation analysis (|R|>0.3, P<0.001) with 19 established cuproptosis genes. To establish a prognostic lncRNA signature for LUAD, univariate Cox regression followed by LASSO and multivariate Cox regression analyses were employed. Validation was performed using Kaplan-Me

SUBMITTER: Lu L 

PROVIDER: S-EPMC12598532 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature